TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Non-randomized, international, multi-centre, open-label, single arm study to determine the
pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide
(KIMOZO) in the pediatric population aged 1 year and over.